CuraGen Advances CR011-vcMMAE int...(inst glycoprotein NMB (GPNMB) attached t...),Health

Date:4/9/2008

inst glycoprotein NMB (GPNMB) attached to a potent, synthetic drug monomethyl auristatin E (MMAE), using Seattle Genetics' proprietary technology. The ADC recognizes GPNMB, a novel, selective target that plays a role in the ability of cancer cells to invade and metastasize. CR011-vcMMAE contains an enzyme-cleavable linker designed to be stable in the bloodstream and to release MMAE after internalization into tumor cells that express GPNMB, resulting in cancer cell death.

ASCO Presentation Details

A poster entitled "A phase I/II study of CR011-vcMMAE, an antibody toxin conjugate drug in patients with unresectable stage III/IV melanoma," is scheduled to be presented by Patrick Hwu, M.D., Ph.D., Professor and Chairman of the Department of Melanoma Medical Oncology at M.D. Anderson Cancer Center, on Sunday, June 1, 2008 from 2:00 - 6:00 p.m. The poster session will be followed by a poster discussion from 5:00 - 6:00 p.m.

About Melanoma

The number of people diagnosed with melanoma is rapidly increasing. It is expected that approximately 60,000 new cases of melanoma will be diagnosed and an estimated 8,000 people in the U.S. will die of the disease during 2008. The prognosis for patients with advanced melanoma is poor, and studies have shown that the median survival is less than nine months.

About CuraGen

CuraGen Corporation (Nasdaq: CRGN) is a dedicated clinical-stage biopharmaceutical company developing diverse approaches for the treatment of cancer including belinostat and CR011-vcMMAE. By leveraging drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promising therapeutics to address the unmet medical needs of cancer patients. CuraGen Corporation is h
'/>"/>

SOURCE CuraGen Corporation Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
2. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
3. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
4. CuraGen Announces Top-Line Phase II Results on Velafermin
5. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
6. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
7. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
8. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
9. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
10. Stem Cell Breakthrough Advances Science Without Ethical Landmines, Says Cardinal
11. Thermo Fisher Scientific Advances Gene-Silencing Technology for Life Sciences Research